SCHEMBL19334408

SCHEMBL19334408

O=C(CCCCCNS(=O)(=O)c1ccc(Br)cc1)NCCc1ccc(Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.67
POLB P06746 3/20 0.67
ALDH1A1 P00352 3/20 0.67
GRK2 P25098 2/20 0.67
RAB9A P51151 2/20 0.65
TSHR P16473 1/20 0.58
TBXA2R P21731 1/20 0.54
EGFR P00533 2/20 0.52
ERBB2 P04626 2/20 0.52
CTDSP1 Q9GZU7 2/20 0.52
LIG1 P18858 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
GPR35 Q9HC97 1/20 0.52
MEN1 O00255 1/20 0.51
TP53 P04637 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19334407 0.91 RAB9A (0.77) KMT2APOLBGRK2RAB9ATBXA2R
SCHEMBL13401887 0.84 HTT (0.68) KMT2APOLBALDH1A1GRK2RAB9A
SCHEMBL19334506 0.81 ALDH1A1 (0.61) KMT2AALDH1A1RAB9ATSHRMEN1
SCHEMBL19334330 0.80 USP2 (0.67) KMT2APOLBALDH1A1GRK2RAB9A
SCHEMBL13401905 0.79 TDP1 (0.70) KMT2APOLBALDH1A1GRK2RAB9A
SCHEMBL19334435 0.79 RAB9A (0.73) KMT2APOLBALDH1A1GRK2RAB9A
SCHEMBL13401886 0.79 ALDH1A1 (0.65) KMT2AALDH1A1RAB9ATBXA2RMEN1
SCHEMBL13401909 0.79 ALDH1A1 (0.65) KMT2APOLBALDH1A1RAB9ATSHR
SCHEMBL19334535 0.78 ALDH1A1 (0.67) KMT2AALDH1A1RAB9ATSHRTBXA2R
SCHEMBL13401910 0.78 KMT2A (0.55) KMT2APOLBALDH1A1GRK2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed